معرفی
Magnus Abrahamson is a Senior Lecturer at Lund University, affiliated with the Division of Clinical Chemistry and Pharmacology. He serves as Research Team Manager for the Protease Inhibitor Research group and Principal Investigator at the Lund University Cancer Centre (LUCC). His research focuses on cystatin C’s role in kidney disease, cancer diagnostics, and amyloidosis treatment. He is also part of EpiHealth: Epidemiology for Health.
His research aims to develop diagnostic tools for kidney diseases (e.g., 'shrunken pore syndrome') and cancer (melanoma), while exploring cystatin C’s potential as an anti-tumor and anti-amyloid agent. Projects include structural studies of cystatin C variants and their clinical applications.
Key contributions include work on cystatin C as a biomarker for kidney function, amyloid formation mechanisms, and therapeutic strategies targeting protease systems. His publications span clinical lab medicine, oncology, and molecular biology.
Abrahamson leads the ALF-funded project on cystatin C’s multifunctional roles and collaborates with international teams. His work aligns with UN Sustainable Development Goals for health and well-being (SDG 3).
